Yes, a big problem, just looking at the 10Q. The

Yes, a big problem, just looking at the 10Q. The company total assets is listed at 18M. Does anyone think that is the true value right now this close to approve after spending $250M to get here? The accounting like this for companies like Cydy in similar positions is flawed in my opinion, they can’t even count money spent on inventory at this point. This deal, which looks like it is still a go, unlocks some of the missing value substantially. Having the BLA accepted unlocks some of the missing value. Drug approval unlocks some of that missing value somehow lost building the foundation. Do what needs to be done to get us to one of those points.